Business Standard

Healthcare index nears all-time high, Sun Pharma zooms

According to Motilal Oswal Financial Services, pharma sector will post 28% year-on-year growth in EBITDA

Related News

Shares of pharmaceutical companies are in limelight with Sun Pharmaceutical Industries, Ipca Laboratories, and Aanjaneya Lifecare are trading at their lifetime highs on the Bombay Stock Exchange (BSE).

The Healthcare index — which tracks the movement of pharma shares on the BSE —the largest gainer among the sectoral indices is up 70 points or 1% at 6,845, trading nears to its lifetime high of 6,871 touched on January 2011.

The index has outperforming by gaining 16.6% year-to-date, compared with 12.5% rise in the benchmark index Sensex.

Sun Pharma Industries is trading higher by 2% at Rs 607, extending its yesterday’s over 2% gain after a favourable verdict from the US Supreme Court in its patent case against Novo Nordisk.

According to Motilal Oswal Financial Services, pharma sector will post 28% year-on-year growth in earnings before interest, taxes, depreciation, and amortization (EBITDA) led by strong performance by Sun Pharma on the back of improvement in the profitability of Taro, and Cadila led by acquisitions, Glenmark Pharma and Torrent Pharma on a low base.

The research firm expects the sector will post a topline growth of 13.5% on year-on-year basis (excluding one-offs) and adjusted profit after tax (PAT) is expected to grow by 12.5% on YoY.

Read more on:   
|
|
|
|
|

Healthcare index nears all-time high, Sun Pharma zooms

According to Motilal Oswal Financial Services, pharma sector will post 28% year-on-year growth in EBITDA

Shares of pharmaceutical companies are in limelight with Sun Pharmaceutical Industries, Ipca Laboratories, Wockhardt and Aanjaneya Lifecare are trading at their lifetime highs on the Bombay Stock Exchange (BSE).

Shares of pharmaceutical companies are in limelight with Sun Pharmaceutical Industries, Ipca Laboratories, and Aanjaneya Lifecare are trading at their lifetime highs on the Bombay Stock Exchange (BSE).

The Healthcare index — which tracks the movement of pharma shares on the BSE —the largest gainer among the sectoral indices is up 70 points or 1% at 6,845, trading nears to its lifetime high of 6,871 touched on January 2011.

The index has outperforming by gaining 16.6% year-to-date, compared with 12.5% rise in the benchmark index Sensex.

Sun Pharma Industries is trading higher by 2% at Rs 607, extending its yesterday’s over 2% gain after a favourable verdict from the US Supreme Court in its patent case against Novo Nordisk.

According to Motilal Oswal Financial Services, pharma sector will post 28% year-on-year growth in earnings before interest, taxes, depreciation, and amortization (EBITDA) led by strong performance by Sun Pharma on the back of improvement in the profitability of Taro, and Cadila led by acquisitions, Glenmark Pharma and Torrent Pharma on a low base.

The research firm expects the sector will post a topline growth of 13.5% on year-on-year basis (excluding one-offs) and adjusted profit after tax (PAT) is expected to grow by 12.5% on YoY.

image

Read More

Credit ratings fell the most in three years: CRISIL

According to CRISIL, the Indian arm of Standard & Poor which rates over 9,000 issuers in India, credit ratings have fallen the most in three ...

Recommended for you

Advertisements

Quick Links

Market News

Nifty ends 77 points lower; Infosys' Q4 earnings weigh

The 30-share Sensex provisionally ended down 252 points at 27,483 and the 50-share Nifty ended down 77 points at 8,321.

Gold recovers on wedding season demand, global cues

Metal adds Rs 190 to Rs 27,190 per 10 grams in National Capital, Silver up Rs 250 to Rs 36,500 per kg

Cairn India rebounds from 52-week low

The moved higher by 3% to Rs 221,bouncing back 9% from its 52-week low of Rs 202 touched on the NSE in early morning trade.

CNX IT index drops 3%; Infosys hits three-month low

Infosys,Tech Mahindra, Rolta India, Polaris Consulting, Tata Elxsi and KPIT Techno were down 4%-9% on the NSE.

Infosys Q4FY15 results impact: Stock falls 4%

By comparison, the CNX IT index slipped 1.7% and the benchmark CNX Nifty lost around 1% in trade at 2:45pm

 

Back to Top